155 related articles for article (PubMed ID: 12206749)
21. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
23. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
24. [Positron emission tomography (PET) in clinical oncology. Part II].
Cabrera Villegas A; Gámez Cenzano C; Martín Urreta JC
Rev Esp Med Nucl; 2002 Apr; 21(2):131-47; quiz 149-51. PubMed ID: 11879626
[No Abstract] [Full Text] [Related]
25. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography.
Miles KA
Australas Radiol; 2001 Feb; 45(1):9-18. PubMed ID: 11259966
[TBL] [Abstract][Full Text] [Related]
26. Segmental
Spadafora M; Pace L; Mansi L
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):1-4. PubMed ID: 27695909
[No Abstract] [Full Text] [Related]
27. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
[TBL] [Abstract][Full Text] [Related]
28. [Current data and perspectives on positron emission tomography oncology-radiotherapy].
Lonneux M; Sibomana M; Pauwels S; Grégoire V
Cancer Radiother; 1999; 3(4):275-88. PubMed ID: 10486538
[TBL] [Abstract][Full Text] [Related]
29. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
[TBL] [Abstract][Full Text] [Related]
30. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
31. Alternative imaging strategy of solitary pulmonary nodule by FDG PET/CT: Can be imagined a tailored PET?
Spadafora M; Evangelista L; Gridelli C; Cuocolo A
Eur J Radiol; 2017 May; 90():188-191. PubMed ID: 28583632
[TBL] [Abstract][Full Text] [Related]
32. Nuclear medicine imaging of lung cancer.
Goldsmith SJ; Kostakoglu L
Radiol Clin North Am; 2000 May; 38(3):511-24. PubMed ID: 10855258
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma.
Stokkel MP; Draisma A; Pauwels EK
J Cancer Res Clin Oncol; 2001 May; 127(5):278-85. PubMed ID: 11355142
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
36. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities.
Sigg MB; Steinert H; Grätz K; Hugenin P; Stoeckli S; Eyrich GK
J Oral Maxillofac Surg; 2003 Sep; 61(9):1022-9. PubMed ID: 12966477
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography scanning is coming to a hospital near you soon!
Bashir H; Shabo G; Nunan TO
Clin Med (Lond); 2008 Apr; 8(2):134-9. PubMed ID: 18478853
[TBL] [Abstract][Full Text] [Related]
38. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.
Ung YC; Maziak DE; Vanderveen JA; Smith CA; Gulenchyn K; Lacchetti C; Evans WK;
J Natl Cancer Inst; 2007 Dec; 99(23):1753-67. PubMed ID: 18042932
[TBL] [Abstract][Full Text] [Related]
39. [Value of Pet-18FDG in lung cancer].
Richter JA; Torre W; Gámez C; Aramendia JM; Crespo A; Nicolás A; Brugarolas A
Med Clin (Barc); 1999 Nov; 113(15):567-71. PubMed ID: 10605681
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
